{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:03:50Z","timestamp":1790129030458,"version":"4.0.1"},"reference-count":81,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000864","name":"The Michael J Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["MJFF-021362"],"award-info":[{"award-number":["MJFF-021362"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["RF1 NS113548-01A1"],"award-info":[{"award-number":["RF1 NS113548-01A1"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.neurot.2026.e01049","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:22:51Z","timestamp":1787023371000},"page":"e01049","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SNCA-targeted transcriptional repression therapy alleviates pathological and behavioral perturbations in a Parkinson's disease mouse model"],"prefix":"10.1016","volume":"23","author":[{"given":"Bernadette","family":"O'Donovan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Rittiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suraj","family":"Upadhya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dellila","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Kantor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ornit","family":"Chiba-Falek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2026.e01049_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01049_bib2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1001\/archneur.58.2.186","article-title":"Synucleinopathies: clinical and pathological implications","volume":"58","author":"Galvin","year":"2001","journal-title":"Arch Neurol"},{"issue":"4","key":"10.1016\/j.neurot.2026.e01049_bib3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1353-8020(99)00031-0","article-title":"Parkinson's disease, dementia with lewy bodies and multiple system atrophy are alpha-synucleinopathies","volume":"5","author":"Spillantini","year":"1999","journal-title":"Parkinsonism Relat Disorders"},{"issue":"Pt 8","key":"10.1016\/j.neurot.2026.e01049_bib4","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/brain\/122.8.1437","article-title":"The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease","volume":"122","author":"Damier","year":"1999","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.neurot.2026.e01049_bib5","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/S1474-4422(09)70238-8","article-title":"Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria","volume":"8","author":"Dickson","year":"2009","journal-title":"Lancet Neurol"},{"issue":"Pt 5","key":"10.1016\/j.neurot.2026.e01049_bib6","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","article-title":"Ageing and Parkinson's disease: substantia nigra regional selectivity","volume":"114","author":"Fearnley","year":"1991","journal-title":"Brain"},{"issue":"6645","key":"10.1016\/j.neurot.2026.e01049_bib7","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.neurot.2026.e01049_bib8","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/mds.25421","article-title":"Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease","volume":"28","author":"Appel-Cresswell","year":"2013","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01049_bib9","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1086\/302486","article-title":"Genetic analysis of families with Parkinson disease that carry the Ala53Thr mutation in the gene encoding alpha-synuclein","volume":"65","author":"Athanassiadou","year":"1999","journal-title":"Am J Hum Genet"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01049_bib10","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1399-0004.2007.00781.x","article-title":"The Ala53Thr mutation in the alpha-synuclein gene in a Korean family with Parkinson disease","volume":"71","author":"Ki","year":"2007","journal-title":"Clin Genet"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01049_bib11","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/ng0298-106","article-title":"Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease","volume":"18","author":"Kruger","year":"1998","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.neurot.2026.e01049_bib12","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/ana.23894","article-title":"G51D alpha-synuclein mutation causes a novel parkinsonian-pyramidal syndrome","volume":"73","author":"Lesage","year":"2013","journal-title":"Ann Neurol"},{"issue":"7","key":"10.1016\/j.neurot.2026.e01049_bib13","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/mds.28534","article-title":"A novel SNCA A30G mutation causes familial Parkinson's Disease","volume":"36","author":"Liu","year":"2021","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01049_bib14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ana.410380306","article-title":"A Greek-American kindred with autosomal dominant, levodopa-responsive parkinsonism and anticipation","volume":"38","author":"Markopoulou","year":"1995","journal-title":"Ann Neurol"},{"issue":"9","key":"10.1016\/j.neurot.2026.e01049_bib15","doi-asserted-by":"crossref","first-page":"2180 e1","DOI":"10.1016\/j.neurobiolaging.2014.03.024","article-title":"Novel alpha-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology","volume":"35","author":"Pasanen","year":"2014","journal-title":"Neurobiol Aging"},{"issue":"5321","key":"10.1016\/j.neurot.2026.e01049_bib16","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the alpha-synuclein gene identified in families with Parkinson's disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01049_bib17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/ana.10795","article-title":"The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia","volume":"55","author":"Zarranz","year":"2004","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01049_bib18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/ana.26153","article-title":"Characterizing the genetic Architecture of Parkinson's Disease in latinos","volume":"90","author":"Loesch","year":"2021","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e01049_bib19","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaneurol.2020.0428","article-title":"Identification of risk loci for parkinson disease in Asians and comparison of risk between Asians and Europeans: a genome-wide Association Study","volume":"77","author":"Foo","year":"2020","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.neurot.2026.e01049_bib20","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jamaneurol.2020.5257","article-title":"Identification of candidate parkinson disease genes by integrating genome-wide Association Study, expression, and epigenetic data sets","volume":"78","author":"Kia","year":"2021","journal-title":"JAMA Neurol"},{"issue":"12","key":"10.1016\/j.neurot.2026.e01049_bib21","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","article-title":"Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies","volume":"18","author":"Nalls","year":"2019","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e01049_bib22","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jama.296.6.661","article-title":"Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease","volume":"296","author":"Maraganore","year":"2006","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.neurot.2026.e01049_bib23","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/hmg\/ddl030","article-title":"Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease","volume":"15","author":"Mizuta","year":"2006","journal-title":"Hum Mol Genet"},{"issue":"4","key":"10.1016\/j.neurot.2026.e01049_bib24","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/ana.20438","article-title":"Multiple regions of alpha-synuclein are associated with Parkinson's disease","volume":"57","author":"Mueller","year":"2005","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01049_bib25","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1600-0404.2008.01019.x","article-title":"Multiple alpha-synuclein gene polymorphisms are associated with Parkinson's disease in a Norwegian population","volume":"118","author":"Myhre","year":"2008","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"10.1016\/j.neurot.2026.e01049_bib26","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/ana.20268","article-title":"alpha-Synuclein promoter confers susceptibility to Parkinson's disease","volume":"56","author":"Pals","year":"2004","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e01049_bib27","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00439-008-0582-9","article-title":"Genomewide association study for susceptibility genes contributing to familial Parkinson disease","volume":"124","author":"Pankratz","year":"2009","journal-title":"Hum Genet"},{"issue":"5-6","key":"10.1016\/j.neurot.2026.e01049_bib28","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.mad.2007.04.002","article-title":"Familial genes in sporadic disease: common variants of alpha-synuclein gene associate with Parkinson's disease","volume":"128","author":"Ross","year":"2007","journal-title":"Mech Ageing Dev"},{"issue":"12","key":"10.1016\/j.neurot.2026.e01049_bib29","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ng.485","article-title":"Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease","volume":"41","author":"Satake","year":"2009","journal-title":"Nat Genet"},{"issue":"12","key":"10.1016\/j.neurot.2026.e01049_bib30","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/ng.487","article-title":"Genome-wide association study reveals genetic risk underlying Parkinson's disease","volume":"41","author":"Simon-Sanchez","year":"2009","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.neurot.2026.e01049_bib31","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/ejhg.2010.254","article-title":"Genome-wide association study confirms extant PD risk loci among the Dutch","volume":"19","author":"Simon-Sanchez","year":"2011","journal-title":"Eur J Hum Genet"},{"issue":"18","key":"10.1016\/j.neurot.2026.e01049_bib32","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1212\/01.wnl.0000275524.15125.f4","article-title":"alpha-Synuclein and Parkinson disease susceptibility","volume":"69","author":"Winkler","year":"2007","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01049_bib33","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41531-023-00580-3","article-title":"Ethnicity- and sex-specific genome wide association study on Parkinson's disease","volume":"9","author":"Park","year":"2023","journal-title":"npj Parkinson's Dis"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01049_bib34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10048-016-0478-0","article-title":"Up-regulation of SNCA gene expression: implications to synucleinopathies","volume":"17","author":"Tagliafierro","year":"2016","journal-title":"Neurogenetics"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01049_bib35","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ana.10846","article-title":"Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications","volume":"55","author":"Farrer","year":"2004","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e01049_bib36","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ana.21380","article-title":"Genomic investigation of alpha-synuclein multiplication and parkinsonism","volume":"63","author":"Ross","year":"2008","journal-title":"Ann Neurol"},{"issue":"5646","key":"10.1016\/j.neurot.2026.e01049_bib37","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1090278","article-title":"alpha-Synuclein locus triplication causes Parkinson's disease","volume":"302","author":"Singleton","year":"2003","journal-title":"Science"},{"issue":"9440","key":"10.1016\/j.neurot.2026.e01049_bib38","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0140-6736(04)17103-1","article-title":"Alpha-synuclein locus duplication as a cause of familial Parkinson's disease","volume":"364","author":"Chartier-Harlin","year":"2004","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.neurot.2026.e01049_bib39","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1002\/mds.21007","article-title":"Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients","volume":"21","author":"Chiba-Falek","year":"2006","journal-title":"Mov Disord"},{"issue":"18","key":"10.1016\/j.neurot.2026.e01049_bib40","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1093\/hmg\/ddu196","article-title":"The genetic contributions of SNCA and LRRK2 genes to Lewy Body pathology in Alzheimer's disease","volume":"23","author":"Linnertz","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"10","key":"10.1016\/j.neurot.2026.e01049_bib41","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jalz.2015.05.011","article-title":"A cytosine-thymine (CT)-rich haplotype in intron 4 of SNCA confers risk for Lewy body pathology in Alzheimer's disease and affects SNCA expression","volume":"11","author":"Lutz","year":"2015","journal-title":"Alzheimer's Dement"},{"issue":"7","key":"10.1016\/j.neurot.2026.e01049_bib42","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkn084","article-title":"Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease","volume":"36","author":"Grundemann","year":"2008","journal-title":"Nucleic Acids Res"},{"issue":"1-2","key":"10.1016\/j.neurot.2026.e01049_bib43","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0006-8993(01)02772-X","article-title":"Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease","volume":"914","author":"Rockenstein","year":"2001","journal-title":"Brain Res"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01049_bib44","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s40478-024-01803-1","article-title":"Single-nucleus multi-omics of Parkinson's disease reveals a glutamatergic neuronal subtype susceptible to gene dysregulation via alteration of transcriptional networks","volume":"12","author":"Shwab","year":"2024","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01049_bib45","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ymthe.2017.11.015","article-title":"Selective alpha-Synuclein knockdown in monoamine neurons by intranasal Oligonucleotide delivery: potential therapy for Parkinson's Disease","volume":"26","author":"Alarcon-Aris","year":"2018","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01049_bib46","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.135633","article-title":"alpha-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease","volume":"6","author":"Cole","year":"2021","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.neurot.2026.e01049_bib47","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1172\/JCI64502","article-title":"shRNA targeting alpha-synuclein prevents neurodegeneration in a Parkinson's disease model","volume":"125","author":"Zharikov","year":"2015","journal-title":"J Clin Investig"},{"key":"10.1016\/j.neurot.2026.e01049_bib48","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fnmol.2018.00036","article-title":"Silencing alpha synuclein in mature nigral neurons results in rapid neuroinflammation and subsequent toxicity","volume":"11","author":"Benskey","year":"2018","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.neurot.2026.e01049_bib49","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fnins.2016.00012","article-title":"Is Alpha-Synuclein loss-of-function a contributor to parkinsonian pathology? Evidence from non-human Primates","volume":"10","author":"Collier","year":"2016","journal-title":"Front Neurosci"},{"issue":"8","key":"10.1016\/j.neurot.2026.e01049_bib50","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/mt.2010.115","article-title":"In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration","volume":"18","author":"Gorbatyuk","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2026.e01049_bib51","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.brainres.2011.04.036","article-title":"An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons","volume":"1395","author":"Khodr","year":"2011","journal-title":"Brain Res"},{"key":"10.1016\/j.neurot.2026.e01049_bib52","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pneurobio.2017.04.004","article-title":"Deregulation of alpha-synuclein in Parkinson's disease: insight from epigenetic structure and transcriptional regulation of SNCA","volume":"154","author":"Guhathakurta","year":"2017","journal-title":"Prog Neurobiol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01049_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci13010150","article-title":"alpha-Synuclein and mechanisms of epigenetic regulation","volume":"13","author":"Surguchov","year":"2023","journal-title":"Brain Sci"},{"issue":"1-2","key":"10.1016\/j.neurot.2026.e01049_bib54","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jns.2013.11.033","article-title":"Hypomethylation of SNCA in blood of patients with sporadic Parkinson's disease","volume":"337","author":"Ai","year":"2014","journal-title":"J Neurol Sci"},{"issue":"11","key":"10.1016\/j.neurot.2026.e01049_bib55","doi-asserted-by":"crossref","first-page":"9031","DOI":"10.1074\/jbc.C110.212589","article-title":"Alpha-synuclein sequesters Dnmt1 from the nucleus: a novel mechanism for epigenetic alterations in Lewy body diseases","volume":"286","author":"Desplats","year":"2011","journal-title":"J Biol Chem"},{"issue":"18","key":"10.1016\/j.neurot.2026.e01049_bib56","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.1523\/JNEUROSCI.6119-09.2010","article-title":"Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains","volume":"30","author":"Jowaed","year":"2010","journal-title":"J Neurosci"},{"issue":"11","key":"10.1016\/j.neurot.2026.e01049_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015522","article-title":"CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease","volume":"5","author":"Matsumoto","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.neurot.2026.e01049_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.652226","article-title":"Cell-Type specific changes in DNA methylation of SNCA intron 1 in synucleinopathy brains","volume":"15","author":"Gu","year":"2021","journal-title":"Front Neurosci"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01049_bib59","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/cns.12059","article-title":"A DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine, exacerbates neurotoxicity and upregulates Parkinson's disease-related genes in dopaminergic neurons","volume":"19","author":"Wang","year":"2013","journal-title":"CNS Neurosci Ther"},{"issue":"11","key":"10.1016\/j.neurot.2026.e01049_bib60","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.ymthe.2018.08.019","article-title":"Downregulation of SNCA expression by targeted editing of DNA methylation: a potential strategy for precision therapy in PD","volume":"26","author":"Kantor","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2026.e01049_bib61","article-title":"Lentiviral Vector platform for the efficient delivery of epigenome-editing tools into human induced pluripotent stem cell-derived disease models","volume":"145","author":"Tagliafierro","year":"2019","journal-title":"J Vis Exp"},{"issue":"16","key":"10.1016\/j.neurot.2026.e01049_bib62","doi-asserted-by":"crossref","first-page":"6048","DOI":"10.1523\/JNEUROSCI.20-16-06048.2000","article-title":"The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity","volume":"20","author":"Ostrerova-Golts","year":"2000","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01049_bib63","doi-asserted-by":"crossref","first-page":"6770","DOI":"10.1038\/s41598-022-10789-6","article-title":"Mechanisms of enhanced aggregation and fibril formation of Parkinson's disease-related variants of alpha-synuclein","volume":"12","author":"Ohgita","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01049_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.102084","article-title":"Neuronal-type-specific epigenome editing to decrease SNCA expression: implications for precision medicine in synucleinopathies","volume":"35","author":"Sun","year":"2024","journal-title":"Mol Ther Nucleic Acids"},{"issue":"7","key":"10.1016\/j.neurot.2026.e01049_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/v13071288","article-title":"Lentiviral vectors for delivery of gene-editing systems based on CRISPR\/Cas: current State and perspectives","volume":"13","author":"Dong","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.neurot.2026.e01049_bib66","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2121-9-2","article-title":"The CMV early enhancer\/chicken beta actin (CAG) promoter can be used to drive transgene expression during the differentiation of murine embryonic stem cells into vascular progenitors","volume":"9","author":"Alexopoulou","year":"2008","journal-title":"BMC Cell Biol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01049_bib67","doi-asserted-by":"crossref","first-page":"7259","DOI":"10.1038\/s41467-024-50515-6","article-title":"The therapeutic implications of all-in-one AAV-delivered epigenome-editing platform in neurodegenerative disorders","volume":"15","author":"Kantor","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurot.2026.e01049_bib68","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3389\/fnmol.2020.00148","article-title":"Gene-Editing technologies paired with viral vectors for translational research into neurodegenerative diseases","volume":"13","author":"Rittiner","year":"2020","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.neurot.2026.e01049_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.1035543","article-title":"Therapeutic modulation of gene expression in the disease state: treatment strategies and approaches for the development of next-generation of the epigenetic drugs","volume":"10","author":"Rittiner","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01049_bib70","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40478-017-0416-x","article-title":"AAV1\/2-induced overexpression of A53T-alpha-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease","volume":"5","author":"Ip","year":"2017","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.neurot.2026.e01049_bib71","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1750-1326-5-43","volume":"5","author":"Koprich","year":"2010","journal-title":"Mol Neurodegener"},{"issue":"11","key":"10.1016\/j.neurot.2026.e01049_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167235","article-title":"Towards a non-human primate model of alpha-synucleinopathy for development of therapeutics for Parkinson's Disease: optimization of AAV1\/2 delivery parameters to drive sustained expression of alpha Synuclein and dopaminergic degeneration in macaque","volume":"11","author":"Koprich","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.neurot.2026.e01049_bib73","article-title":"Limitations of animal models of Parkinson's disease","volume":"2011","author":"Potashkin","year":"2010","journal-title":"Parkinsons Dis"},{"issue":"10","key":"10.1016\/j.neurot.2026.e01049_bib74","doi-asserted-by":"crossref","first-page":"7830","DOI":"10.1007\/s12035-024-03974-3","article-title":"The Alpha-Synuclein gene (SNCA) is a genomic target of Methyl-CpG binding protein 2 (MeCP2)-Implications for Parkinson's Disease and Rett Syndrome","volume":"61","author":"Schmitt","year":"2024","journal-title":"Mol Neurobiol"},{"issue":"11","key":"10.1016\/j.neurot.2026.e01049_bib75","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112413","article-title":"Higher vulnerability and stress sensitivity of neuronal precursor cells carrying an alpha-synuclein gene triplication","volume":"9","author":"Flierl","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.neurot.2026.e01049_bib76","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012122","article-title":"Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra","volume":"5","author":"McCormack","year":"2010","journal-title":"PLoS One"},{"issue":"Pt 8","key":"10.1016\/j.neurot.2026.e01049_bib77","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1093\/brain\/awt192","article-title":"Disease duration and the integrity of the nigrostriatal system in Parkinson's disease","volume":"136","author":"Kordower","year":"2013","journal-title":"Brain"},{"issue":"5456","key":"10.1016\/j.neurot.2026.e01049_bib78","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1126\/science.287.5456.1265","article-title":"Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders","volume":"287","author":"Masliah","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.neurot.2026.e01049_bib79","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/B978-0-12-800149-3.00002-0","article-title":"Clinical applications involving CNS gene transfer","volume":"87","author":"Kantor","year":"2014","journal-title":"Adv Genet"},{"key":"10.1016\/j.neurot.2026.e01049_bib80","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.omtm.2017.04.002","article-title":"Integrase-Deficient lentiviral vector as an all-in-one platform for highly efficient CRISPR\/Cas9-Mediated gene editing","volume":"5","author":"Ortinski","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01049_bib81","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Targeted Ther"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926002199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926002199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:09:50Z","timestamp":1790125790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926002199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":81,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1878747926002199"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e01049","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SNCA-targeted transcriptional repression therapy alleviates pathological and behavioral perturbations in a Parkinson's disease mouse model","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e01049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e01049"}}